115 related articles for article (PubMed ID: 11460203)
1. Cost of drugs manufactured by the university hospital--role of the Central Pharmacy.
Marin ML; Chaves CE; Zanini AC; Faintuch J; Faintuch D; Cipriano SL
Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(2):41-6. PubMed ID: 11460203
[TBL] [Abstract][Full Text] [Related]
2. [The role of the cytostatic drugs unit in rationalization of hospital drugs management--the case study and the analysis of drug utilization].
Zuziak S; Topór-Madry R; Pilc A; Bochenek T
Pol Merkur Lekarski; 2014 Jul; 37(217):43-8. PubMed ID: 25154199
[TBL] [Abstract][Full Text] [Related]
3. [Economical assessment of intravenous mixture centralization].
Martínez-Tutor MJ
Farm Hosp; 2006; 30(6):351-8. PubMed ID: 17298192
[TBL] [Abstract][Full Text] [Related]
4. Purchasing premixed products.
Geberbauer CW
J Healthc Mater Manage; 1988; 6(2):40, 42, 44-5. PubMed ID: 10286278
[TBL] [Abstract][Full Text] [Related]
5. Economic assessment of aseptic compounding rooms in hospital pharmacies in five European countries.
Dekyndt B; Décaudin B; Lannoy D; Odou P
J Oncol Pharm Pract; 2015 Apr; 21(2):102-10. PubMed ID: 24519187
[TBL] [Abstract][Full Text] [Related]
6. [Costs of a cytostatic drug preparation unit in a hospital in Mexico].
Martínez Rodríguez OA; Rivas Bocanegra RE; Ascencio-Pérez IS; Zapata Sánchez LA
Farm Hosp; 2007; 31(6):375-8. PubMed ID: 18348668
[TBL] [Abstract][Full Text] [Related]
7. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
8. The high cost of customization: compounding drugs.
Cohen MR
Hosp Pharm; 1991 Apr; 26(4):384-5. PubMed ID: 10113578
[TBL] [Abstract][Full Text] [Related]
9. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach.
Hamblin S; Rumbaugh K; Miller R
J Trauma Acute Care Surg; 2012 Dec; 73(6):1484-90. PubMed ID: 23064610
[TBL] [Abstract][Full Text] [Related]
10. Justification of a pharmacy intravenous admixture service in an Australian hospital.
Plumridge RJ; Maher M
Am J Hosp Pharm; 1993 Mar; 50(3):463-6. PubMed ID: 8442462
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital.
Cazarim MS; Rodrigues JPV; Calcini PS; Einarson TR; Pereira LRL
Rev Saude Publica; 2020; 54():94. PubMed ID: 33027344
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacy-managed drug supply may reduce drug expenditure in hospitals].
Trapnes E; Gløersen E; Mordal K; Refsum N
Tidsskr Nor Laegeforen; 2005 May; 125(9):1205-6. PubMed ID: 15880162
[TBL] [Abstract][Full Text] [Related]
13. Impact of the implementation of vasoactive drug protocols on costs in the treatment of critically ill patients.
Cuesta-López I; Sánchez-Cuervo M; Candela-Toha Á; Benedí-González J; Bermejo-Vicedo T
Farm Hosp; 2018 Mar; 42(2):62-67. PubMed ID: 29501057
[TBL] [Abstract][Full Text] [Related]
14. Preparation times and costs for various solutions used for continuous renal replacement therapy.
Shaw AR; Chaijamorn W; Clark JS; Mueller BA
Am J Health Syst Pharm; 2018 Jun; 75(11):808-815. PubMed ID: 29802114
[TBL] [Abstract][Full Text] [Related]
15. Pharmacy costs associated with nonformulary drug requests.
Sweet BV; Stevenson JG
Am J Health Syst Pharm; 2001 Sep; 58(18):1746-52. PubMed ID: 11571818
[TBL] [Abstract][Full Text] [Related]
16. [Containing pharmacy costs in an emergency department].
Ucha Samartín M; Martínez López de Castro N; Pichel Loureiro A; Amador Barciela L
Rev Calid Asist; 2012; 27(5):298-9. PubMed ID: 22704689
[No Abstract] [Full Text] [Related]
17. Evaluation of cost minimization strategies of anaesthetic drugs in a tertiary care hospital.
Hawkes C; Miller D; Martineau R; Hull K; Hopkins H; Tierney M
Can J Anaesth; 1994 Oct; 41(10):894-901. PubMed ID: 8001207
[TBL] [Abstract][Full Text] [Related]
18. Reusing cytostatics in a centralised pharmacy preparation unit.
Ramos Linares S; Merino Alonso J; Román González N; Tévar Alfonso E; Díaz Ruíz P; Gorchs Molist M
Farm Hosp; 2011; 35(2):70-4. PubMed ID: 20869287
[TBL] [Abstract][Full Text] [Related]
19. The financial impact of investigational drug services.
Rogers SD; Lampasona V; Buchanan EC
Top Hosp Pharm Manage; 1994 Apr; 14(1):60-6. PubMed ID: 10133561
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of mixing clindamycin and aminoglycosides.
Abel SR; Olson SM
Am J Hosp Pharm; 1987 Jun; 44(6):1385-7. PubMed ID: 3618617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
